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Abstract 
 
Objectives: To describe the epidemiology and geographical differences in prevalence of congenital 
cerebral anomalies in Europe.    
 
Design and Setting: Congenital cerebral anomalies (ICD10 code Q04) recorded in 29 population-based 
EUROCAT registries conducting surveillance of 1.7 million births per annum (29% of all European births). 
Participants: All birth outcomes (livebirths, fetal deaths from 20 weeks gestation and terminations of 
pregnancy after prenatal diagnosis of a fetal anomaly (TOPFA)) from 2005-2014. 
 
Main outcome measures: Prevalence, proportion of associated non-cerebral anomalies, prenatal 
detection rate. 
 
Results: 4927 cases with congenital cerebral anomalies were identified; a prevalence (adjusted for under-
reporting) of 9.8 (95% CI: 8.5 to 11.2) per 10,000 births. There was a six-fold difference in prevalence 
across the registries. Registries with higher proportions of prenatal diagnoses had higher prevalence.  
Overall, 55% of all cases were liveborn, 3% were fetal deaths and 41% resulted in TOPFA. Forty-eight 
percent of all cases were an isolated cerebral anomaly, 25% had associated non-cerebral anomalies and 
27% were chromosomal or part of a syndrome (genetic or teratogenic). The prevalence excluding genetic 
or chromosomal conditions increased by 2.4% per annum (95%CI: 1.3% - 3.5%), with the increases 
occurring only for congenital malformations of the corpus callosum (3.0% per annum) and “other 
reduction deformities of the brain” (2.8% per annum). 
 
Conclusion: Only half of the cases were isolated cerebral anomalies. Improved pre- and postnatal 
diagnosis may account for the increase in prevalence of congenital cerebral anomalies from 2005 to 
2014. However, major differences in prevalence remain between regions. 
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INTRODUCTION 
It is important to have background information about the epidemiology of congenital cerebral anomalies 
including associated anomalies and trends over time. This enables a knowledge-based evaluation of 
possible future changes in the prevalence and associated anomalies, which could be related to the 
occurrence of new teratogens. For example, Maternal Zika virus infection is acknowledged to increase the 
risk of microcephaly occurring in the fetus[1, 2].  However, there is more uncertainty as to the association 
of maternal Zika virus infections with other structural cerebral anomalies[3]. 
EUROCAT)is a European network of population-based registries for the epidemiologic surveillance of 
congenital anomalies ( http://www.eurocat-network.eu/) [4, 5]. There are many EUROCAT publications on 
neural tube defects [6-8],  microcephaly [9], hydrocephaly [10] and septo-optic dysplasia  [11].  Individual 
EUROCAT registries have published data on corpus callosum anomalies in Emilia Romagna [12],  
schizencephaly [13] and holoprosencephaly [14] in the UK. However, the epidemiology of these and other 
cerebral anomalies from the Q04 chapter in ICD10 such as reduction defects of the brain, microgyria, 
megalencephaly, cerebral cysts and schizencephaly have never been analysed at a European level and most 
of these anomalies are quite rare with little published epidemiological data. A previous EUROCAT 
collaboration with the Surveillance of Cerebral Palsy in Europe  network has shown that the majority of 
congenital anomalies in children with cerebral palsy are cerebral anomalies [15, 16], indicating the severity 
of the clinical outcome of these congenital anomalies. 
Most cerebral anomalies are not recognised at birth, but may be diagnosed pre- and postnatally by 
ultrasound scans and other imaging examinations including  magnetic resonance imaging (MRI). As 
diagnostic methods, prenatally and in the neonatal period, are known to vary over time, and between 
countries in Europe, and because some registries include late diagnosed cases up to five years of age or 
more, major European differences in the prevalence of cerebral anomalies are expected. 
The aim of this study was to describe the epidemiology of specific congenital cerebral anomalies in Europe 
and the observed geographical differences in prevalence using EUROCAT data.    
 
METHODS 
The EUROCAT registries are population based; the geographically defined populations and the 
methodology of collecting individual case data for EUROCAT is described elsewhere [4]. The registries 
ascertain congenital anomalies cases from multiple sources, using active case finding and passive 
notification, such as hospital discharge diagnoses, birth and death certificates and post mortem 
examinations. Information about livebirths (LB), fetal deaths (FD) with a gestational age (GA)  20 weeks 
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and terminations of pregnancy after prenatal diagnosis of congenital anomaly (TOPFA) at any gestation is 
included. All major structural congenital anomalies, syndromes and chromosomal anomalies are included in 
the database. Minor anomalies are excluded based on a list of ICD10 codes for exclusion (EUROCAT Guide 
1.4)[17]. The congenital anomalies have been coded according to ICD10 with the British Paediatric 
Association (BPA) extension since 2005.  
All full member registries were invited to take part in the study and data from 29 EUROCAT registries are 
included. Data was extracted from the EUROCAT database on 31/05/2017 (Table 1). All birth outcomes (LB, 
FD and TOPFA) with an ICD10 code within the subchapter Q04 ‘Other congenital malformations of brain’ 
and born in the years 2005-2014  were included. The anomalies included in Q04 are congenital anomalies 
of corpus callosum (Q040), arhinencephaly (Q041), holoprosencephaly (Q042), other reduction deformities 
of brain (Q043), septo-optic dysplasia (Q044), megalencephaly (Q045), congenital cerebral cysts (Q046), 
other specified anomalies of brain (Q048) and unspecified congenital anomalies of brain (Q049). Some 
registries added the 4th digit code from British Associations extension of ICD10 for Q043 for further 
specification (agyria/ lissenencephaly, microgyria/polygyria, hydranencephaly, reduction anomalies of 
cerebrum, reduction anomalies of cerebellum). A previous paper has reported  data from the cases with 
septo-optic dysplasia [11], which for completeness are also included in this paper. Not all registries 
contributed data for all 10 years. Data about each case included year of birth, type of birth, GA at birth or 
termination, infant sex, time of diagnosis, maternal age and associated congenital anomalies. 
 
Classification of the congenital anomalies 
Cases were classified as isolated cerebral anomalies, chromosomal cases, teratogenic or genetic syndromes 
or multiple congenital anomalies (anomalies from other organ systems plus a cerebral anomaly) according 
to the EUROCAT multiple congenital anomaly flowchart [18] and manual review of the written text 
description of the anomalies. Cases with additional codes and/or written text description of microcephaly, 
ventriculomegaly and hydrocephaly were classified as isolated cerebral anomalies. Combinations of 
cerebral anomalies within the Q04 chapter were classified hierarchically according to Table 2 so that all 
cases were allocated to one main cerebral anomaly diagnosis - diagnoses on the left taking precedence 
over those on the right. The diagnoses of single cerebral cyst, arachnoid and choroid plexus cysts and 
anomalies of septum pellucidum are on the EUROCAT list of minor anomalies for exclusion and these cases 
were therefore excluded, if described in the written text as the only cerebral anomaly. Cases with written 
text description of large cisterna magna, asymmetric ventricles or minor ventriculomegaly (<15 mm) were 
excluded if these were the only cerebral anomalies. Colpocephaly was classified as a secondary anomaly if 
associated with agenesis of corpus callosum. There are no specific ICD10 codes for the most frequent 
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cerebral syndromes (Joubert, Aicardi, Walker-Warburg and Miller-Dieker syndrome) and these are reported 
based on written text descriptions. There were no written text descriptions for cases from the registries in 
Paris and Norway and Northern England (NorCAS) used standard written text. Trends over time are 
presented as pan-European trends excluding genetic cases (chromosomal anomaly or genetic syndrome). 
 
Method to Identify Under-reporting 
A previous study of septo-optic dysplasia [11] found evidence that some registries were under-reporting 
cases and developed a method to estimate the prevalence adjusting for this under-reporting. In brief, for 
each separate anomaly, the average prevalence amongst the 15 registries with the highest prevalence is 
calculated using a random effects meta-analysis. The average prevalence of the whole population is then 
estimated by adjusting the prevalence observed in these 15 registries by factors to adjust for the fact that 
these registries have the highest prevalence estimate amongst 29 registries. These factors depend only on 
the average number of cases in the registries. The factors are obtained by simulation and calculation of the 
ratio of the mean prevalence of 15 out of 29 registries compared to the mean prevalence of all 29 registries 
assuming the number of cases follows a Poisson distribution with an expected value equal to the observed 
median number of cases in the 15 registries. For example, if only 2 cases are observed in each registry the 
correction factor is 1.7, whereas if 75 cases are observed the correction factor is only 1.09.  
 
Statistical Analysis 
The prevalence of the anomalies and the trends over time were investigated by fitting Poisson regression 
multi-level models with registry as a random effect. Associations between prevalence and prenatal 
diagnosis rates and the length of follow-up a registry performs (that is up to what age they still collect 
diagnoses classified into within 1 week, within 1 year and over 1 year) were investigated using Poisson 
regression with prenatal diagnosis and length of follow-up as  covariates.  All other exploratory analyses 
between anomalies were investigated using ANOVA and chi-squared tests according to whether the 
variable of interest was categorical or not. 
 
RESULTS 
The study included 4927 cases with a congenital cerebral anomaly giving an overall prevalence (adjusted 
for under-reporting) of 9.8 (95% CI: 8.5 to 11.2) per 10,000 births in the 29 registries. There were major 
differences in prevalence by registry (Table 1, Figure 1), with more than a six-fold difference between the 
registry with the lowest prevalence (South Portugal; 2.7 per 10,000) and the registry with the highest 
prevalence (French West Indies; 16.6 per 10,000). The proportions of cases that were diagnosed prenatally 
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varied considerably between registries. There was an association between prevalence and the proportion 
of prenatal diagnoses; registries with higher proportions of prenatal diagnoses had a higher prevalence 
(p=0.029; Figure 2), but significant heterogeneity between registers still remained. There was no 
association between length of follow-up performed by the registry and the prevalence (p=0.5). 
Congenital malformations of the corpus callosum and “other reduction deformities of the brain” were the 
most common cerebral anomalies, with an adjusted prevalence of 3.3 (95%CI 2.7 - 3.8) and 2.9 (95%CI 2.5 – 
3.4) respectively. The adjusted prevalence of holoprosencephaly was 1.6 (95%CI: 1.4 - 1.8) per 10,000 births 
and of megalencephaly was 0.08 (95%CI: 0.05 - 0.11) per 10,000 births.   
Overall 3448 cases were diagnosed prenatally (70% of the total, ranging from 50% to 94% amongst  
registries) and of these 2043 resulted in a TOPFA (59% of the prenatally diagnosed cases). The prenatal 
diagnosis may have occurred due to a different anomaly, we cannot distinguish which anomaly was 
diagnosed first .  Overall 55% of cases were livebirths, 3% fetal deaths  and 41% TOPFAs, with large 
variation between registries and cerebral anomaly. livebirthsPregnancies with septo-optic dysplasia were 
most likely to result in a live birth (96%) and pregnancies with arhinencephaly least likely to result in a live 
birth (4%). Overall, 28% of all livebirths were born preterm (GA < 37 weeks) which varied according to 
anomaly; babies with septo-optic dysplasia and megalencephaly were the least likely to be born preterm 
(19% and 17% respectively) (Table 2).   
The average maternal age for all cases of cerebral anomalies was 29.9 years. The mean maternal age was 
significantly lower in cases of septo-optic dysplasia (23.4 years).   
For all the cases , 48% were isolated cerebral anomalies, 25% were classified as multiple congenital 
anomalies, 18% had an associated chromosomal anomaly (6% had Patau syndrome) and for 9% a syndrome 
was diagnosed (Table 3). The most common associated anomalies were congenital heart defects (CHDs; 
9%) and septal defects (ASD and VSD) were the most frequent CHDs. Cases with arhinencephaly or 
holoprosencephaly were more likely to have a chromosomal anomaly (46% and 36% respectively), 
particularly Patau syndrome (33% and 24% respectively). In contrast, cases with septo-optic dysplasia, 
megalencephaly or cerebral cysts were more likely to be isolated cerebral anomalies (72%, 71% and 67% 
respectively). The most common genetic syndromes reported were Joubert syndrome (23 cases) and 
Aicardi syndrome (13 cases). 
Figures 3a-d show that the pan-European prevalence of cases with cerebral anomalies not due to genetic or 
chromosomal conditions has increased from 2005 to 2014 by 2.4% per annum (94%CI: 1.3% to 3.5%), with 
the increases occurring  for congenital malformations of the corpus callosum by 3.0% (0.8% to 5.3%) and 
“other reduction deformities of the brain” by 2.8% (0.5% to 5.0%).  These significant increases in prevalence 
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remained  after adjusting for increases in prenatal diagnoses and  for the length of follow-up in the 
registries 
 
DISCUSSION 
The overall prevalence (adjusted for under-reporting) of major congenital cerebral anomalies in Europe 
from 2005-2014 was 9.8 (95%CI: 8.5 – 11.2) per 10,000 births. The prevalence of non-genetic, non-
chromosomal anomalies of corpus callosum and of other reduction defects of brain significantly increased, 
while the prevalences of the other cerebral anomalies were stable. The increases may be due to increased 
prenatal diagnosis as if cerebral anomalies are not diagnosed prenatally, they may not be diagnosed for 
several years of age until they emerge in relation to the diagnosis of developmental problems or cerebral 
palsy[16].  
Our adjusted prevalence for corpus callosum anomalies of 3.3 (95%CI: 2.72 – 3.82 ) per 10,000 births with 
66% LBs was consistent with  two other smaller  studies of 38 and 630 cases which did not include fetal 
losses or TOPFAs [20, 21]. The study from California 1983-2003 [21] showed a prevalence of corpus 
callosum anomalies  1.8 per 10,000 births and the study from Hungary from 1992-2006 showed a 
prevalence of  2.05 per 10,000 livebirths [20] . The Californian study found 17% of cases had a 
chromosomal anomaly similar to the 16% in our study)[21]. The increased risk of preterm birth was also 
observed in our study [21] . 
The adjusted prevalence of holoprosencephaly was 1.6 (95%CI: 1.4 - 1.8) per 10,000 births. A literature 
review including 21 studies found that the prevalence of holoprosencephaly varied between 0.5 to 1.5 per 
10,000 births [22]. The authors concluded that the differences in prevalence were mainly explained by the 
inclusion criteria (LBs or all pregnancy outcomes including early TOPFA). These studies also found a higher 
female rate and a high proportion of chromosomal cases as in our study (63% were female and 36% were 
chromosomal cases).  
Our study showed an adjusted prevalence of megalencephaly of 0.08 (95%CI: 0.05 - 0.11) per 10,000 births. 
To our knowledge, there are no published prevalence figures for this anomaly. Most case series and reports 
describe megalencephaly as an isolated anomaly [23], which is in line with our findings (71% isolated). A 
study from a tertiary center in the USA described that almost half of their patients with unilateral 
megalencephaly had an additional syndrome diagnosis [23]. Tinkle et al [23] report a Japanese study that 
found 11 of 38 patients (29%) had a syndrome diagnosis (Sasaki et al 2000 – in Japanese so not referenced). 
In our study, we found a syndrome diagnosis in 16% of cases. 
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Our study showed  an adjusted prevalence of arhinencephaly of 0.04 (95%CI: 0.01 – 0.07) per 10,000 births. 
The only study we  identified  reported a prevalence of  arhinencephaly of 0.14 (95%CI : 0.06 - 0.25) per 
10,000 births in Atlanta [24] and included only 10 cases, while our study included 46 cases. 
The prevalence of our remaining three groups (cerebral cysts (Q046), other specified cerebral anomalies 
(Q048) and unspecified cerebral anomalies (Q049)) is more heterogeneous and therefore difficult to 
compare with other studies. Cases with congenital cerebral cysts were mainly liveborn (81%), mainly non-
genetic (87%) and half of the cases were diagnosed prenatally. Some cases coded Q048 had the written 
text description “ventriculomegaly”. The EUROCAT definition of hydrocephaly (ICD10 codes in Q03) is a size 
of the lateral ventricles at 15 mm or more. Cases with an unspecified size of the lateral ventricles or a size 
at 10-14 mm may have been reported to EUROCAT with the code Q048 for other specified cerebral 
anomalies. Less than half of the cases reported with unspecified cerebral anomaly were liveborn, indicating 
the severity of the anomalies but lack of diagnostic details in the EUROCAT registries. 
The association between prevalence and prenatal detection rate explains part of the European 
heterogeneity in the prevalence of cerebral anomalies. In addition, Fetal MRI may be used more frequently 
in some areas and may  increase the detection rate [25]. However, under-ascertainment of cases by the 
registry may also explain the very low prevalence in some registries. In other registries, there may be over-
reporting of minor anomalies seen on cerebral imaging or by reporting cerebral injuries after preterm birth 
or birth asphyxia using ICD codes from the congenital anomaly chapter. The diagnosis of reduction defect of 
the cerebellum, often with the written text “small cerebellum” was mainly reported by the English 
registries and there may be different diagnostic criteria for reporting this anomaly. For some cerebral 
anomalies, in particular reduction defects, the critical exposure period includes up to gestational week 18 
[26]. If ultrasound screening is performed at an earlier  GA cases may be missed.  
 
There was a high rate of TOPFAs for the anomalies included in this study indicating the severity of cerebral 
anomalies. Overall, 41% of all cases were TOPFA with the highest TOPFA rate found for arhinencephaly 
(91%) and holoprosencephaly (78%). For anomalies of corpus callosum, the TOPFA rate was 31%, possibly 
due to more severe cerebral anomalies being present. Counselling and parental decision-making after 
prenatal diagnosis of anomalies of corpus callosum is difficult [27]. A study has shown that 25-30% of 
fetuses with a prenatal diagnosis of isolated agenesis of corpus callosum have developmental delays [28].  
However, a recent study on the use of MR Imaging on fetuses with a suspected brain abnormality on 
ultrasound showed that fetal MRI changed the prognostic information in 20% of the cases [25]. 
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Strengths and limitations 
The strength of our study is it is the largest covering 6.4 million births in Europe. All registries use the same 
inclusion criteria for major anomalies and the same coding and classification system for congenital 
anomalies.  There may be underreporting of cases in some registries, but this is adjusted for in the method 
for calculating the European prevalence of specific anomalies (which does assume that all populations are 
at equal risk of occurrence of the congenital anomalies of interest which may not be the case). There may 
also be some over-reporting of minor anomalies, reporting of diagnosis related to birth complications or  
misclassification of congenital hydrocephaly as ventriculomegaly. 
 
CONCLUSIONS. 
Our study provides background prevalence information in the time period before the outbreak of the  Zika 
virus . During this period increasing prevalence was reported due to better prenatal detection. 
Heterogeneity in prevalence between regions of Europe may be explained by differences in the prenatal 
diagnoses and by underreporting of major anomalies in some registries and reporting of minor anomalies 
as major in other registries. 
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Table 1: Number of cases with a congenital cerebral anomaly (ICD10 code Q04),, prevalence and proportion 
prenatally diagnosed in 29 EUROCAT registries in the period 2005-2014 
Registry, Country  
Years of data Population 
births 
(1000) 
Total 
Cases 
Prevalence per 
10,000 births 
Proportion 
prenatally 
diagnosed (%) 
South Portugal 2006-2014 161 44 2.7 68 
South East Ireland 2005-2014 75 27 3.6 59 
Zagreb, Croatia 2005-2014 58 24 4.1 71 
Wessex, UK 2005-2014 298 156 5.2 86 
E Midlands & S 
Yorkshire, UK 
2005-2012 587 311 5.3 83 
Tuscany, Italy 2005-2014 300 167 5.6 81 
Norway 2005-2012 487 273 5.6 61 
Malta 2005-2014 41 25 6.1 36 
Cork and Kerry, Ireland 2005-2014 99 60 6.1 48 
Hainaut, Belgium 2005-2014 126 85 6.7 72 
Emilia Romagna, Italy 2005-2014 400 276 6.9 70 
Valencia Region, Spain 2005-2014 403 278 6.9 59 
Northern England, UK 2005-2014 331 231 7.0 71 
Mainz, Germany 2005-2014 32 23 7.2 78 
Ukraine 2005-2014 304 219 7.2 60 
Thames Valley, UK 2005-2014 300 221 7.4 77 
Northern Netherlands 2005-2014 174 130 7.5 62 
Odense, Denmark 2005-2013 41 34 8.4 65 
Wales, UK 2005-2014 347 305 8.8 64 
Saxony Anhalt, Germany 2005-2014 172 153 8.9 50 
Antwerp, Belgium 2005-2014 206 185 9.0 56 
Styria, Austria 2005-2012 83 77 9.3 75 
Basque Country, Spain 2007-2014 205 201 9.8 77 
South West England, UK 2005-2014 496 491 9.9 51 
Isle de Reunion, France 2005-2014 146 176 12.1 78 
Brittany, France 2011-2014 145 182 12.5 89 
Vaud, Switzerland 2005-2014 79 122 15.4 73 
Paris, France 2005-2012 214 352 16.5 94 
French West Indies, 
France 
2009-2014 60 99 16.6 92 
      
Total 2005-2014 6368 4927 
9.78 
(95%CI:  
8.50 - 11.16)1 
70 
 
1 :Total prevalence is adjusted for potential under-reporting (see methods)  
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 Table 2: Epidemiology data for congenital cerebral anomaly cases in29 EUROCAT registries from2005-2014 with cerebral anomaly cases classified 
according to one main cerebral anomaly category with the diagnoses present on the left taking precedence over the ones on the right 
ICD 10 Code  Q04.2 Q04.1 Q04.4 Q04.5 Q04.3 Q04.0 Q04.8 Q04.6 Q04.9 Q04 
Anomaly 
Holopros-
encephaly 
Arhin-
encephaly 
Septo-optic 
dysplasia 
Megal-
encephaly 
Other 
reduction 
deformities 
of brain 
Congenital 
malformations 
of corpus 
callosum 
Other 
specified 
congenital 
malformations 
of brain 
Congenital 
cerebral cysts 
Congenital 
malformation 
of brain, 
unspecified 
All Cases 
No. of Cases 865 33 94 49 1,409 1,476 383 375 243 4927 
No. of diagnoses1 865 46 99 49 1,464 1,748 550 555 273 5649 
Prevalence per 
10,000 births 
(95%CI)2 
1.55 
(1.37 - 1.77) 
0.04 
(0.01 - 0.07) 
0.19 
(0.11 - 0.26) 
0.08 
(0.05 - 0.11) 
2.92 
(2.51 - 3.35) 
3.25 
(2.72 - 3.82) 
0.75 
(0.53 - 1.01) 
0.69 
(0.49 - 0.93) 
0.39 
(0.29 - 0.52) 
9.78 
(8.5 - 11.16) 
Live births No. (%) 155 (18) 2 (6) 90 (96) 33 (67) 792 (56) 975 (66) 259 (68) 302 (81) 112 (46) 2720 (55) 
Fetal Deaths No. 
(%) 34 (4) 1 (3) 0 (0) 1 (2) 55 (4) 37 (3) 12 (3) 6 (2) 18 (7) 
164 (3) 
TOPFA No. (%) 676 (78) 30 (91) 4 (4) 15 (31) 562 (40) 464 (31) 112 (29) 67 (18) 113 (47) 2043 (41) 
Non-genetic No. 
(%) 539 (62) 12 (36) 91 (97) 43 (88) 1119 (79) 1156 (78) 307 (80) 325 (87) 192 (79) 
3784 (77) 
Average maternal 
age (years) 30 (30 - 31) 32 (30 - 34) 23 (22 - 24) 30 (28 - 32) 30 (30 - 30) 30 (30 - 31) 30 (30 - 31) 29 (28 - 30) 29 (29 - 30) 
30 (30-30) 
 Preterm birth 
(GA < 37 weeks) 
livebirths No. (%) 62 (40) 1 (50) 17 (19) 5 (17) 229 (29) 208 (22) 79 (31) 113 (38) 34 (32) 748 (28) 
Prenatal 
Diagnosis No. (%) 811 (94) 32 (97) 32 (34) 27 (55) 962 (68) 1038 (70) 207 (54) 182 (49) 157 (65) 3448 (70) 
Male No.  (%)  316 (37) 14 (42) 52 (55) 29 (59) 684 (49) 749 (51) 198 (52) 196 (52) 114 (47) 2352 (48) 
 
1: Number of diagnoses will be greater than the number of cases as each case may have more than one different diagnoses of a cerebral anomaly 
2 : Adjusted for potential under-reporting (see methods).  
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Table 3: Classification of congenital cerebral anomaly cases according to associated anomalies and genetic diagnosis; 29 EUROCAT registries, 2005-
2014   
ICD 10 Code Q04.2 Q04.1 Q04.4 Q04.5 Q04.3 Q04.0 Q04.8 Q04.6 Q04.9 Q04 
Associated 
anomalies and 
genetic 
diagnoses 
 No. (%) 
Holopros-
encephaly 
Arhin-
encephaly 
Septo-
optic 
dysplasia 
Megal-
encephaly 
Other 
reduction 
deformities 
of brain 
Congenital 
malform-
ations of 
corpus 
callosum 
Other specified 
congenital 
malform-ations 
of brain 
Congenital 
cerebral 
cysts 
Congenital 
malformation 
of brain, 
unspecified 
All Cases 
Isolated cerebral 
anomaly 
305 (35) 2 (6) 68 (72) 35 (71) 663 (47) 764 (52) 180 (47) 251 (67) 112 (46) 2380 (48) 
Chromosomal 309 (36) 21 (46) 1 (1) 0 (0) 203 (14) 280 (16) 68 (12) 43 (8) 39 (14) 876 (18) 
Patau syndrome 206 (24) 11 (33) 0 (0) 0 (0) 31 (2) 24 (2) 2 (1) 0 (0) 11 (5) 285 (6) 
Edward’s 
syndrome 
31 (4) 1 (3) 0 (0) 0 (0) 50 (4) 55 (4) 10 (3) 24 (6) 7 (3) 178 (4) 
Down’s 
syndrome 
3 (0) 0 (0) 1 (1) 0 (0) 23 (2) 17 (1) 11 (3) 1 (0) 6 (2) 62 (1) 
Genetic 
syndrome 
13 (2) 4 (12) 1 (1) 8 (16) 152 (11) 92 (6) 31 (8) 15 (4) 13 (5) 329 (7) 
Teratogenic 
syndromes incl 
maternal 
infections1  
0 (0) 0 (0) 1 (1) 0 (0) 34 (2) 17 (1) 15 (4) 9 (2) 13 (5) 89 (2) 
Multiple 
congenital 
anomaly 
238 (28) 10 (30) 23 (24) 6 (12) 372 (26) 364 (25) 109 (28) 63 (17) 68 (28) 1253 (25) 
 with congenital 
heart defects  68 (8) 3 (9) 8 (9) 1 (2) 133 (9) 143 (10) 40 (10) 22 (6) 30 (12) 448 (9) 
with congenital 
limb anomalies 42 (5) 2 (6) 4 (4) 3 (6) 125 (9) 94 (6) 26 (7) 13 (3) 17 (7) 326 (7) 
with congenital 
eye anomalies 46 (5) 2 (6) 9 (10) 0 (0) 21 (1) 43 (3) 6 (2) 8 (2) 5 (2) 140 (3) 
1  Underreporting is likely to have occurred  
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